Clinical Trials Directory

Trials / Completed

CompletedNCT02792842

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of ART-123

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
79 (actual)
Sponsor
Asahi Kasei Therapeutics Corporation · Industry
Sex
All
Age
20 Years – 79 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of ART-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage II / III colon cancer.

Conditions

Interventions

TypeNameDescription
DRUGART-123 (3-day ART)ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
DRUGART-123 (1-day ART)ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
DRUGPlaceboPlacebo infusion once daily on days 1-3 in each cycle

Timeline

Start date
2016-07-01
Primary completion
2018-02-01
Completion
2018-02-01
First posted
2016-06-08
Last updated
2024-04-04
Results posted
2024-04-04

Locations

2 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT02792842. Inclusion in this directory is not an endorsement.